for intravenous use Initial U.S. Approval: 2018
Elzonris (tagraxofusp-erzs) is a medication used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
Facts about tagraxofusp-erzs-injection
Disease Indications -Leukemia
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “tagraxofusp-erzs-injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For tagraxofusp-erzs-injection
Approved accessible "tagraxofusp-erzs-injection"
Tagraxofusp-erzs injection is approved by USFDA for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged above 2 years. There is a chance for liver damage. Patients should be monitored for liver enzymes regularly. Most common side effects reported with tagraxofusp-erzs are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia(high temperature) and weight gain. Most common laboratory abnormalities are decreased albumin, platelets, hemoglobin, calcium, sodium, and increased glucose.
Elzonris is a medicine used to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of blood cancer which can affect many organs including the skin, the bone marrow (the spongy tissue inside the large bones) and the lymph nodes. BPDCN is rare, and Elzonris was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 11 November 2015.
How can 1 go about obtaining tagraxofusp-erzs-injection?
To access tagraxofusp-erzs-injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)
Elzonris (tagraxofusp-erzs injection) for intravenous use Initial U.S. Approval: 2018
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398